Physician profile
Denise D Perkins
NPI 1609283456
$1,902.71
in general payments reported to CMS, 2019-2025
21 companies · $562 in 2025
The $562 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $145 · 2022: $415 · 2023: $320 · 2024: $461 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,342.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $378.67 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $306.53 | 2021-2024 | |
| Pfizer INC. | $180.77 | 2021-2025 | |
| Lilly USA, LLC | $177.40 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.19 | 2021-2024 | Jardiance |
| Glaxosmithkline, LLC. | $148.38 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $112.55 | 2022-2025 | Airsupra, Enhertu, Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $71.53 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $63.41 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Biohaven Pharmaceutical Holding Company LTD. | $42.75 | 2022 | |
| Axsome Therapeutics, INC. | $39.59 | 2025 | Auvelity |
| Abbott Laboratories | $37.03 | 2022-2023 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $34.02 | 2022-2024 | Trintellix |
| Exact Sciences Corporation | $30.99 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $24.80 | 2025 | Voquezna |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $21.44 | 2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $18.75 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $16.77 | 2024 | Rexulti |
| Solventum Corporation | $16.47 | 2024 | Prevena, Prevena Restor Bellaform |
| Astellas Pharma US INC | $16.31 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.36 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Perkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.